Between the moment a prescription is written and the moment a payer reimburses it, there is no single system that verifies the prescriber was authorized, the patient was eligible, the drug was appropriate, and the claim wasn't already paid. Medisyns is that system.
Every figure in the public record — every fraud estimate, every loss statistic — reflects only what was caught. The number that wasn't caught is structurally unknowable, because the infrastructure to know it has never been built.
Public health systems reimburse prescriptions through disconnected networks: provincial or national registries that track who is enrolled, insurer systems that track what is covered, prescriber registries that track who is licensed, and pharmacy dispensing systems that track what was filled. None of these systems speak to each other in real time at the point of dispensing.
The result is a reimbursement process that relies on periodic audits, manual inspection, and after-the-fact anomaly detection — none of which prevent fraud. They can only discover it, long after the money has left.
Every jurisdiction has built parts of the answer in isolation. Medisyns is the protocol layer that connects them.
The distinction matters. A product replaces something. A protocol connects everything that already exists. Medisyns does not ask health systems to abandon their infrastructure. It gives that infrastructure a verification layer it has never had.
Like TCP/IP standardized how computers communicate, Medisyns standardizes how prescription verification events are communicated across parties. The protocol is governed by Medisyns Inc. Any compliant system — provincial, national, insurer, pharmacy — can integrate without vendor lock-in.
The commercial model reflects this. Medisyns charges per verified transaction, not a flat licence. The cost is tied directly to the fraud it prevents — making the ROI case self-evident at any scale of adoption.
An Ontario-incorporated company. Protocol standards are maintained by Medisyns with a commitment to open interoperability. No proprietary lock-in for adopting jurisdictions.
The protocol architecture and verification logic are protected by patent applications filed in both jurisdictions. Medisyns is not a repackaged EHR — it is a novel infrastructure layer.
Designed to meet PIPEDA, GDPR, ITSG-33, FHIR R4, and SOC 2 Type II requirements. Compliance is architectural — not retrofitted. ITSG-33 and SOC 2 Type II certifications in progress.
Cost is tied directly to verified transactions. The ROI case is self-funding: the fee is a fraction of the fraud each transaction prevents. Pilot caps available for initial deployments.
Medisyns enters through jurisdictions with the most acute fraud exposure and the most developed existing infrastructure. Each adoption builds the evidence base and the interoperability standard that the next jurisdiction requires.
Canada's provincial drug plan structure creates a direct entry point for Medisyns. Each province operates its own drug plan, insurer network, and pharmacy infrastructure — with no unified real-time verification layer across any of them.
The NHS is structurally analogous to a Canadian provincial health system — a single public payer reimbursing prescriptions across a national formulary. The Counter Fraud Authority has documented £256M in annual prescription fraud losses with no real-time point-of-dispensing verification in place.
The EU's European Medicines Verification System (EMVS) authenticates drug packaging at the point of dispensing — but does not perform payer-side reimbursement fraud verification. The reimbursement layer is entirely unaddressed across all 27 member states.
If you work in or with a public health system and you recognize this problem — there is no minimum scope to reach out. Leave your details and we'll be in touch within 48 hours.